CD200 Limits Monopoiesis and Monocyte Recruitment in Atherosclerosis

Autor: Christina Kassiteridi, Aditi Upadhye, Patricia Green, Esther Lutgens, Anusha N. Seneviratne, Annelie Shami, Tanyaporn Pattarabanjird, Inhye Park, Angela M. Taylor, Keith M. Channon, Ashok Handa, Coleen A. McNamara, Jennifer Cole, Richard O. Williams, Mika Falck-Hansen, Thibault Griseri, Claudia Monaco, Michael E. Goddard
Přispěvatelé: Medical Biochemistry, ACS - Atherosclerosis & ischemic syndromes, AII - Inflammatory diseases
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Male
CCR2
Physiology
Mice
Knockout
ApoE

Coronary Artery Disease
030204 cardiovascular system & hematology
Monocytes
0302 clinical medicine
Orexin Receptors
Macrophage
Phosphorylation
Aorta
Cells
Cultured

Original Research
Aged
80 and over

Membrane Glycoproteins
Middle Aged
Plaque
Atherosclerotic

Chemotaxis
Leukocyte

medicine.anatomical_structure
STAT1 Transcription Factor
monocyte
ComputingMethodologies_DOCUMENTANDTEXTPROCESSING
Female
medicine.symptom
Cardiology and Cardiovascular Medicine
Signal Transduction
Neointima
Adult
bone marrow
Aortic Diseases
Inflammation
macrophage
03 medical and health sciences
Monocytosis
Antigens
CD

medicine
Animals
Humans
Aged
business.industry
Monocyte
Macrophages
medicine.disease
Immune checkpoint
Mice
Inbred C57BL

Disease Models
Animal

030104 developmental biology
inflammation
Cancer research
Leukopoiesis
Bone marrow
atherosclerosis
business
Zdroj: Circulation Research
Circulation research, 129(2), 280-295. Lippincott Williams and Wilkins
ISSN: 1524-4571
0009-7330
Popis: Supplemental Digital Content is available in the text.
Rationale: Inflammation is a basic component of the pathogenesis of atherosclerosis. CD200 is an immune checkpoint known to control macrophage activation. CD200 recently emerged in the Framingham Heart Study and 2 other cohorts as being potentially relevant in cardiovascular disease. The role of this pathway in cardiovascular disease is unknown. Objective: We sought to examine the role of CD200 in atherosclerosis. Methods and Results: Using hypercholesterolemic apolipoprotein-E deficient mice, we demonstrate that whole-body CD200 deficiency augments atherosclerotic lesion formation and vulnerability. Administration of a CD200-Fusion protein reduces neointima formation. Our data show that the CD200-CD200R pathway restrains activation of CD200R+ lesional macrophages, their production of CCR2 ligands, and monocyte recruitment in vitro and in vivo in an air pouch model. Loss of CD200 leads to an excessive accumulation of classical Ly6Chi monocytes and CCR2+ macrophages within the atherosclerotic aorta, as assessed by mass cytometry. Moreover, we uncover a previously uncharacterized effect of the CD200/CD200R pathway in limiting dysregulated monopoiesis and Ly6Chi monocytosis in hypercholesterolemic mice. Bone marrow chimera experiments demonstrate that the CD200-CD20R pathway enables 2 complementary and tissue-dependent strategies to limit atherogenesis: CD200 expression by bone marrow–derived cells limits systemic monocytosis, while CD200 expression by nonhematopoietic cells, for example, endothelial cells, prevents local plaque growth. We show that CD200R signaling controls monopoiesis and macrophage activation through inhibiting phosphorylation of STAT1 (signal transducer and activator of transcription 1). Finally, CD200R expression on classical monocytes in peripheral blood of patients with coronary artery disease is associated with a lower burden of coronary artery disease and a more favorable Virtual Histology plaque profile. Conclusions: The CD200 checkpoint is a key-limiting factor for monopoiesis, monocyte-macrophage activation, and recruitment in atherosclerosis with conserved features in human and mouse. It thus offers a novel potential therapeutic pathway to treat cardiovascular disease.
Databáze: OpenAIRE